DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 80 patients (estimated)
- Sponsors
- Novartis
- Tags
- NLRP3 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1752
- NCT Identifier
- NCT05552469
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.